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ABSTRACT
Objective: To describe drug use, sexual risks and the
prevalence of blood-borne viral infections among men
who inject image and performance enhancing drugs
(IPEDs).
Design: A voluntary unlinked-anonymous cross-
sectional biobehavioural survey.
Setting: 19 needle and syringe programmes across
England and Wales.
Participants: 395 men who had injected IPEDs.
Results: Of the participants (median age 28 years),
36% had used IPEDs for <5 years. Anabolic steroids
(86%), growth hormone (32%) and human chorionic
gonadotropin (16%) were most frequently injected,
with 88% injecting intramuscularly and 39%
subcutaneously. Two-thirds also used IPEDs
orally. Recent psychoactive drug use was common
(46% cocaine, 12% amphetamine), 5% had ever
injected a psychoactive drug and 9% had shared
injecting equipment. ‘Viagra/Cialis’ was used by 7%,
with 89% reporting anal/vaginal sex in the preceding
year (20% had 5+ female-partners, 3% male-partners)
and 13% always using condoms. Overall, 1.5% had
HIV, 9% had antibodies to the hepatitis B core antigen
(anti-HBc) and 5% to hepatitis C (anti-HCV). In
multivariate analysis, having HIV was associated with:
seeking advice from a sexual health clinic; having had
an injection site abscess/wound; and having male
partners. After excluding those reporting male
partners or injecting psychoactive drugs, 0.8% had
HIV, 8% anti-HBc and 5% anti-HCV. Only 23%
reported uptake of the hepatitis B vaccine, and
diagnostic testing uptake was poor (31% for HIV, 22%
for hepatitis C).
Conclusions: Previous prevalence studies had not
found HIV among IPED injectors. HIV prevalence in
this, the largest study of blood-borne viruses among
IPED injectors, was similar to that among injectors of
psychoactive drugs. Findings indicate a need for
targeted interventions.
ARTICLE SUMMARY
Article focus
▪ The Vulnerability to infection of people who
inject drugs is widely recognised; however,
studies have rarely focused on users of image
and performance enhancing drugs. These drugs
can be used to change one’s appearance for aes-
thetic reasons, as well as to improve
performance.
▪ Over the last decade, the number of men using
needle and syringe programmes who report inject-
ing image and performance enhancing drugs has
risen in England and Wales; as a result, there has
been increased concern about the levels of blood-
borne viral infections in this group.
▪ This study describes the nature of drug use and
the risk behaviours in this population, as well as
the prevalence of HIV, hepatitis B and C.
Key messages
▪ The overall prevalence of HIV among men injecting
image and performance enhancing drugs was
similar to that among those injecting psychoactive
drugs in England and Wales. Previous prevalence
studies of people who inject image and
performance enhancing drugs had not detected
HIV.
▪ When the results of this study are compared with
those of a previous study undertaken in England
and Wales in the mid-1990s, they suggest that the
prevalence of hepatitis B infection among injectors
of image and performance enhancing drugs might
have increased over time.
▪ Sexual risk behaviours and psychoactive drug use
were common among injectors of image and
performance enhancing drugs, and the sharing of
injecting equipment was also reported. The uptake
of diagnostic testing for blood borne-viral infections
and the vaccine against hepatitis B was low.
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INTRODUCTION
The vulnerability of people who inject drugs (PWID) to
HIV and other infections is widely recognised; however,
studies have focused on individuals who inject psychoactive
drugs (such as opiates and stimulants) rather than on
those who inject drugs to enhance image and perform-
ance.1–4 The number of injectors of image and
performance enhancing drugs (IPEDs) in contact with
needle and syringe programmes (NSPs) has grown sub-
stantially in the UK,5 and there has been increasing
concern about the use of IPEDs and the associated harms
in the UK and elsewhere.3 5–11
A range of illicit drugs can be injected with the aim of
changing image and performance. These drugs range
from tanning drugs, such as ‘Melanotan-II’,12 to those
used in body-building, such as human growth
hormone.3 13 The most commonly injected and studied
IPEDs are anabolic steroids (AS).3 5 IPEDs are taken both
orally and by injection, with some being predominantly
injected and others being taken only orally. Many users of
these substances also take an array of different drugs.3 5 14
The use, and particularly the injection of IPEDs has been
associated with a range of harms including infections
caused by bacteria15–19 and blood-borne viruses
(BBVs).6 20–25
In England and Wales (E&W), surveillance of HIV
and viral hepatitis among PWID is undertaken through
an annual unlinked-anonymous survey26 27 targeted at
injectors of psychoactive drugs. A very small number of
IPED injectors participated in this survey20; among the
149 sampled during the 1990s, 2% had antibodies to the
hepatitis B core antigen (anti-HBc, a marker of having
ever been infected with hepatitis B virus (HBV))) and
none had antibodies to HIV (anti-HIV).20 In a surveil-
lance study of NSP clients in Australia, 1.6% (n=318) of
those participating over a 10-year period reported
steroid injection, with 10% having antibodies to hepatitis
C virus (anti-HCV) and none having anti-HIV.21 Only
one other survey of IPED injectors has collected bio-
logical samples; this study purposively recruited 63 AS
injectors in Victoria, Australia and found that 12% had
anti-HBc, 9.5% anti-HCV and none anti-HIV.6 A second
Australian study found that half of the IPED users
sampled had ever experienced an injection-related
health problem, with 6% having ever had an abscess.8
A number of other UK studies have recruited IPED
injectors, principally AS injectors; however, none of these
collected biological samples. These studies were mostly
small (N<100), and typically recruited through gyms,28–33
with two recruiting gay men.34 35 The prevalence of ever
sharing injecting equipment in these studies ranged from
0.3% to 6%,20 28–30 32 but in one study it was 20%.33 The
sharing of drug vials was more common (2.4%35; 9.9%34;
23%32). Studies elsewhere have found similar levels of
equipment sharing.6 8 IPED users also report using psy-
choactive drugs, particularly stimulants, though the
reported injection of psychoactive drugs is rare.6 8 28 35 36
IPED users also tend to have more sexual partners than
their comparison groups20 28 and report risky sexual beha-
viours20 32 and low levels of condom use,28 34 suggesting
an elevated risk for HIV infection through sexual activity.
During 2010 and 2011, in response to the increasing
concerns about IPED use, a targeted survey was under-
taken as part of the ongoing unlinked-anonymous survey
of PWID. The aim of this survey was to describe the:
(1) patterns of drug use and injecting risk; (2) sexual
behaviours and (3) BBV prevalence among IPED injec-
tors. As far as we are aware, this is the largest study, and
the ﬁrst outside Australia, to purposively recruit IPED
injectors to measure the prevalence of anti-HIV,
anti-HBc and anti-HCV.
METHODS
Recruitment
In E&W, PWID have been recruited into a voluntary
unlinked-anonymous monitoring survey since 1990, and
the methodological details of this cross-sectional survey
have been published previously.26 27 37 Brieﬂy, agencies
providing services to PWID (eg, NSPs and addiction
treatment) at sentinel locations throughout E&W invite
clients who have ever injected to participate. Sentinel
sites are selected so as to reﬂect the geographic distribu-
tion and range of services offered to PWID. Those who
consent to participate (overall refusal rate during 2010/
2011, 4.7%) provide a biological sample and self-
complete a brief questionnaire focused on psychoactive
drug use.26 27 37 The survey has multisite ethics approval.
This study purposively recruited IPED injectors through
19 sites that provided NSPs. Participants were recruited
either when attending an NSP site or through outreach
provision; they provided an oral-ﬂuid sample and self-
completed a short, specially developed, questionnaire
focused on IPED use (types of drug used and routes of
administration), related behaviours (injecting practices
and sexual behaviours) and health service use.
Laboratory methods
Oral-ﬂuid specimens were collected using the OraSure
device (OraSure Technologies Inc, Pennsylvania, USA).
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This study recruited image and performance enhancing drug
users through needle and syringe programmes. Injectors of these
drugs who are not in contact with these services may have a dif-
ferent risk profile and levels of infection.
▪ Oral-fluid testing was used to detect antibodies to HIV, hepa-
titis B and C; however, tests on these samples for anti-HCV
and anti-HBc have reduced sensitivity.
▪ This is the largest study of blood-borne viruses among men who
inject image and performance enhancing drugs; however, the
sample size still restricts its power. Consequently, caution is
needed when attempting to generalise these findings.
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These were tested for anti-HIV using an in-house
GACELISA with similar performance to GACELISA HIV
1+2 (Abbott Murex Diagnostics Ltd, Dartford, UK).
Reactive specimens underwent further testing according
to a proven algorithm that included a second ELISA
and Western blot (sensitivity and speciﬁcity approaches
100%38). Anti-HCV testing employed a previously vali-
dated commercial enzyme-immunoassay (Ortho HCV
3.0 SAVe, Ortho Diagnostics) with 92% sensitivity and
99% speciﬁcity,39 and for anti-HBc an in-house IgG class-
speciﬁc antibody capture EIA procedure was used which
had an estimated sensitivity of 75% and speciﬁcity of
99% ( JV Parry and A Judd, personal communication).
The oral-ﬂuid sample quality was veriﬁed by testing each
sample for the presence of a predetermined minimum
quantity of total IgG (1 mg/L) employing an in-house
ELISA method.
Analyses
Descriptive analyses were ﬁrst undertaken, and then
bivariate associations (p<0.05) between outcome vari-
ables (anti-HIV, anti-HBc and anti-HCV positivity, equip-
ment sharing and condom use) and covariates (age, drug
use, sexual practice and health services use; table 1) were
examined using Fisher’s exact (when expected cell fre-
quencies <5) and Pearson’s χ2 tests. Where possible asso-
ciations were found (p<0.10), these were further
examined through logistic regression models using the
forward stepwise procedures to select variables, with
selection based on the likelihood ratio test (p<0.05). All
analyses were undertaken using SPSS V.19.
RESULTS
Between May 2010 and May 2011, 400 IPED injectors parti-
cipated in this study; ﬁve (1.25%) women were excluded
from the analyses (due to the small number). The partici-
pants’ characteristics and health service usage are sum-
marised in table 1. Of those reporting their age (88%,
n=347), a quarter (27%) were aged <25 years. During the
preceding year, 45% had seen a general practitioner and
28% had taken the prescribed medication.
Drug use
Details of the participants’ IPED use during the preced-
ing year are given in table 1. AS were the most com-
monly injected IPED (86%). Over half of the
participants reported consuming these orally (57%), a
third reported injecting growth hormone (32%) and
almost a quarter reported using oral antioestrogens
(23%). Overall, 65% (n=252) had taken an IPED orally
during the preceding year, with 58 (23%) of these
having taken two types orally, and 85 (34%) ≥3 types.
Most had injected only one type of IPED during the pre-
ceding year; however, 87 (22%) had injected two types
and 58 (15%) ≥3 types. Considering injecting and oral
use, 71 (18%) had taken two types of IPED and 133
(34%) ≥3 during the preceding year.
Those who injected human growth hormone were
more likely to be older (aged >35 years) than those who
had not (37% (47/128) vs 22% (60/267), p<0.001);
there were no other signiﬁcant differences in the IPEDs
used by age. During the preceding year, most of the par-
ticipants (74%) reported that they had usually injected
themselves, and the majority (88%) had injected intra-
muscularly (table 1).
The participants also reported psychoactive drug use
(table 1), with 46% snorting cocaine and 12% snorting,
drinking or swallowing amphetamine during the preced-
ing year. Ever having injected a psychoactive drug
(including heroin and cocaine) was reported by 4.8%
(table 1). Those who had injected a psychoactive drug
were more likely to report injecting insulin as an IPED
than those who had not (21% (4/19) vs 4.8% (18/376),
p=0.016); there were no other signiﬁcant differences in
the IPEDs used between those who had injected psycho-
active drugs and those who had not.
Overall, 8.9% (95% CI 6.4% to 12%) reported having
ever shared a needle/syringe or drugs vial (table 1); 27
(6.8%) had just shared a vial, 6 (1.5%) had just shared a
needle/syringe and 2 (0.51%) had shared both. Factors
associated with sharing are summarised in table 2. In
the multivariable analysis, ever having shared a needle/
syringe or drug vial was associated with having ever
injected a psychoactive drug, having sought advice from
an sexual health/sexual transmitted infections (SH/
STI) clinic, subcutaneous injection and having snorted,
drunk or swallowed amphetamine (table 2).
Sexual behaviour
Nine-tenths (89%, 350/395) reported having anal or
vaginal sex in the preceding year, and 9.1% (36/395)
had ≥10 partners (table 1). Considering just female
partners, 20% (80/395) of respondents had ≥5 partners.
Thirteen (3.3%) reported ≥1 male sexual partner
during the preceding year (table 1). Those reporting
male sexual partners were older than those who did not
(median age 38 years, IQR 12; and 28 years, IQR 11,
respectively). Those reporting male sexual partners were
also more likely to have ever injected a psychoactive
drug (23% (3/13) vs 4.2% (16/382), p=0.020), more
likely to report snorting, drinking or swallowing amphet-
amine during the last year (46% (6/13) vs 11%
(41/382), p=0.002), and a higher proportion reported
snorting cocaine, but this was not signiﬁcant (62% (8/
13) vs 45% (173/382), p=0.248). Those reporting male
sexual partners were also more likely to report having
ever shared a needle/syringe or vial (25% (4/13) vs
8.1% (31/382), p=0.021). A higher proportion of those
reporting male sexual partners reported always using
condoms during the last year, but this difference was not
signiﬁcant (38% (5/13) vs 19% (73/382), p=0.146).
There were no differences in the types of IPED used,
nor in their routes of administration, between those
reporting male partners and those not.
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Table 1 Characteristics of male injectors of the IPEDs sampled
Characteristic n
Demographic
Age, years Under25 27% 106
25-34 34% 134
35 and over 27% 107
Median (IQR) 28 (13)
Not reported 12% 48
Had ever been in prison 16% 63
Health service use
Had ever used a Needle and Syringe Programme 75% 298
Had seen a general practitioner in the last year about their health 45% 178
Had you got advice at an Accident & Emergency / Walk-in in the last year 16% 64
Had taken/used prescribed medication in last year 28% 111
Had sought advice from a sexual health / sexually transmitted infections clinic in the last year 17% 68
Had been vaccinated against hepatitis B 23% 90
Had had a blood test for hepatitis C 22% 85
Had had a blood test for HIV 31% 122
Symptom of injury or infection at injection site
Had ever had redness at an injection site 43% 168
Had ever had an injection site abscess/sore/open wound 6.80% 27
Image and performance enhancing drug use, last year
Years since first used an image and performance enhancing drug 0-4 36% 141
5+ 32% 128
Median (IQR) 4 (8)
Not reported 32% 126
Oral anabolic steroids 57% 226
Oral anti-oestrogens 23% 92
Oral clenbuterol 15% 60
Oral ephedrine 20% 78
Oral thyroid hormones 9% 37
Oral phosphodiesterase type 5 inhibitor (PDE5i; “Viagra/Calias”) 6.6% 26
Oral other image and performance enhancing drug (inc. Diuretics,
2,4–dinitrophenol and Pro/designer)
12% 46
Injected anabolic steroids 86% 340
Injected growth hormone 32% 128
Injected human chorionic gonadotropin (hCG) 16% 62
Injected insulin injected 5.6% 22
Injected melanotan 8.6% 34
Injected other image and performance enhancing drug (inc. ethryopoetin,
insulin–like growth factor 1 and nalbuphine hydrochloride)
5.1% 20
Use of other illicit drugs
Ever injected illicit drug other than an image and performance enhancing drug. 4.8% 19
Snorted cocaine in the last year 46% 181
Snorted, drunk or swallowed amphetamine in last year 12% 47
Injecting practice
Who usually injected you, last year? Someone else 17% 68
Myself 74% 294
Not reported 8.4% 33
Intramuscular injection in the last year 88% 346
Subcutaneous injection in the last year 39% 154
Ever shared needle, syringe or vial 8.9% 35
Sexual behaviour
Number of sexual partners last year One 38% 152
Two or more 47% 187
Not reported/no sex 14% 56
Gender of sexual partners last year Male partner(s) 3.3% 13
No male partners 82% 323
Not reported/no sex 15% 59
Always condom (anal/vaginal sex) or no sex last year 20% 78
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Table 2 Factors associated with risk behaviours among the IPEDs sampled
Total Yes
Unadjusted odds
ratio with 95% CI
Adjusted odds ratio
with 95% CI
Ever shared a needle, syringe or vial 395 35 8.9%
Number of sexual partners in the last year
One 152 8 5.3% 0.3 0.12 – 0.94 *
Two or more 187 19 10% 0.7 0.28 – 1.6
Not reported/no sex 56 8 14% 1.0
Pearson χ2 test p= 0.088
Gender of sexual partners in the last year
Male partner(s) 13 4 31% 5.5 1.6 – 19 *
No male partners 323 24 7.4% 1.0
Not reported/no sex 59 7 12% 1.7 0.69 – 4.1
Pearson χ2 test p= 0.010
Injected illicit drugs other than IPED
Yes 19 7 37% 7.2 2.6 – 20 6.3 2.1 – 19
No/not reported 376 28 7.4% 1.0 1.0
Fisher’s exact test p= 0.001
Have you got advice from a SH/STI clinic in the last year?
Yes 68 11 16% 2.4 1.1 – 5.2 2.2 1.0 – 5.1
No/not sure 327 24 7.3% 1.0 1.0
Pearson χ2 test p= 0.020
Injected growth hormone (as IPED)
Yes 128 18 14% 2.4 1.2 – 4.8 *
No 267 17 6.4% 1.0
Pearson χ2 test p= 0.012
Injected Insulin (as IPED)
Yes 22 5 23% 3.4 1.2 – 9.8 *
No 373 30 8.0% 1.0
Fisher’s exact test p= 0.035
Subcutaneous injection in the last year?
Yes 154 21 14% 2.6 1.3 – 5.2 3.0 1.4 – 6.5
No/not sure 241 14 6% 1.0 1.0
Pearson χ2 test p= 0.008
Snorted cocaine in the last year?
Yes 181 22 12% 2.1 1.0 – 4.4 *
No 214 13 6.1% 1.0
Pearson χ2 test p= 0.034
Snorted, drunk or swallowed amphetamine in the last year?
Yes 47 11 23% 4.1 1.9 – 9.1 4.1 1.7 – 9.8
No 348 24 6.9% 1.0 1.0
Pearson χ2 test p= 0.0002
Always used condom for anal/vaginal sex 350 48 14%
Gender of sexual partners in the last year
Male partner(s) 13 5 38% 8.1 0.8 – 83 14 1.3 – 155
No male partners 323 42 13% 1.9 0.25 – 15 2.8 0.35 – 22
Not reported 14 1 7.1% 1.0 1.0
Pearson χ2 test p= 0.025
Have you ever had a blood test for hepatitis C?
Yes 82 17 21% 3.2 1.1 – 9 *
No 201 26 13% 1.8 0.68 – 5.0
Not sure 67 5 7.5% 1.0
Pearson χ2 test p= 0.057
Injected anabolic steroids
Yes 304 46 15% 3.9 0.92 – 17 4.2 0.96 – 18
No 46 2 4.3% 1.0 1.0
Pearson χ2 test p= 0.048
Continued
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Among those who reported sex during the preceding
year, 14% (95% CI 11% to 18%, 48/350) had always used
condoms. Factors associated with condom use are given in
table 2. Always using condoms among those who had had
sex during the preceding year was associated in the multi-
variable analysis with having had a male sexual partner
and having not snorted cocaine (table 2).
BBV prevalence
Overall, 1.5% (95% CI 0.7% to 3.3%; n=6) had anti-HIV,
8.8% (95% CI 6.4% to 12%) had ever been infected
with hepatitis B (26 anti-HBc positive, adjusted for test
sensitivity of 0.75) and 5.5% (95% CI 3.7% to 8.2%)
with hepatitis C (20 anti-HCV positive, adjusted for test
sensitivity of 0.92). Covariates associated with anti-HIV,
anti-HBc or anti-HCV positivity are given in table 3. In
the multivariable analysis, anti-HIV positivity was asso-
ciated with having male sexual partners in the preceding
year, ever having an abscess/sore/open wound at the
injection site, and having sought advice from an SH/STI
clinic in the preceding year (table 3). Having anti-HBc
was associated in the multivariable analysis with having
obtained advice from an SH/STI clinic and having not
injected oneself subcutaneously in the preceding year
(table 3). Anti-HCV positivity was associated with having
ever injected a psychoactive drug and having taken a
phosphodiesterase type 5 inhibitor (PDE5i) in the pre-
ceding year in the multivariable analysis (table 3).
After excluding those who reported either sex with men
or having ever injected a psychoactive drug, 0.8% had
anti-HIV (95% CI 0.28% to 2.4%, 3/366), 8.0% anti-HBc
(95% CI 5.6% to 11%, adjusted for test sensitivity, 22/366)
and 4.7% anti-HCV (95% CI 2.9% to 7.3%, adjusted for
test sensitivity, 16/366), with 10% (95% CI 7.7% to 14%,
38/366) having one or more of these three markers. In
this group, having anti-HIV was found to be associated
only with ever having had an abscess/wound at an injec-
tion site (8% (2/25) vs 0.29% (1/341) for those who had
not, p=0.013), and having anti-HBc was only associated
with having sought advice from an SH/STI clinic in the
preceding year (16% (9/56) vs 4.2% (13/310) for those
who had not, p=0.002). The use of three types of IPEDs
was associated with having anti-HCV: having taken a PDE5i
(21% (5/24) vs 3.2% (11/342) for those who had not,
p=0.002); having injected insulin as an IPED (18% (3/17)
vs 3.7% (13/349) for those who had not, p=0.032); and
having injected a less commonly used IPED (17% (3/18)
vs 3.7% (13/348) for those who had not, p=0.037).
In total, 47 (12%, 95% CI 9.1% to 15%) were positive
for one or more of the anti-HIV, anti-HBc and anti-HCV,
with 43 having just one of these markers and four having
two or more of these markers. Two had anti-HBc and
anti-HCV, one of these reported injected psychoactive
drugs, and neither reported having had sex with men.
One, who reported sex with men and injecting psycho-
active drugs, had anti-HIV and anti-HBc; the remaining
participant had all three markers and did not report
either sex with men or injecting psychoactive drugs.
Uptake of interventions related to the three BBV
infections was poor. Overall, only 23% reported receiv-
ing a dose of HBV vaccine, 31% ever having a diagnostic
HIV test and 22% having an HCV test (table 1).
DISCUSSION
IPED injectors are at risk of infection with HIV as well as
other BBVs. This is the ﬁrst prevalence study to have
found HIV among IPED injectors, with the prevalence at
1.5%, similar to that found among injectors of psycho-
active drugs in England and Wales (1.2%, 201140).
However, anti-HBc and anti-HCV—at 8.8% and 5.5%,
respectively—are lower than among psychoactive drug
injectors (16% and 43%, respectively, 201140). The
prevalence of all three BBVs in this sample would
appear to be higher than that found in the general UK
population.41 42 Once those who reported either sex
with men or injecting psychoactive drugs were excluded,
10% had been infected with one or more of HIV, hepa-
titis B and C.
It is important to consider the limitations of this study.
The comparative rarity, marginalisation and illicit nature
of injecting drug use impede the construction of a sam-
pling frame, making the representativeness of our
sample impossible to measure. This study used an estab-
lished methodology for recruiting PWID through spe-
cialist services26 27; however, the robustness of this
Table 2 Continued
Total Yes
Unadjusted odds
ratio with 95% CI
Adjusted odds ratio
with 95% CI
Intramuscular injection in the last year?
Yes 310 46 15% 3.3 0.77 – 14 *
No/not sure 40 2 5.0% 1.0
Pearson χ2 test p= 0.089
Snorted cocaine in the last year?
Yes 162 11 7% 0.3 0.1 – 0.6 0.2 0.12 – 0.52
No 188 37 20% 1.0 1.0
Pearson χ2 test p= 0.0005
*Not in final model.
IPED, image and performance enhancing drugs; SH/STI, sexual health or sexual transmitted infections clinic.
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Table 3 Factors associated the blood-borne virus infections among the IPEDs sampled
Total Positive
Unadjusted odds
ratio with 95% CI
Adjusted odds ratio
with 95% CI
HIV 395 6 1.5%
Age, years*
Aged<35 or age unknown 287 1 0.3% 1.0 *
Aged 35 or over 102 5 4.9% 14 1.62 – 122
Fisher’s exact test p= 0.006
Gender of sexual partners in the last year*
Male sexual partner 13 3 23% 38 6.79 – 211 *
No male partner/no sex 382 3 0.8% 1
Fisher’s exact test p= 0.001
Gender of sexual partners in the last year and age (in years)*
Male sexual partner 13 3 23% 85 8.13 – 893 79 4.29 – 1450
No Male partners, aged <35 or age not reported 285 1 0.4% 1.0 1.0
No male partners, aged 35 or over 97 2 2.1% 6 0.54 – 67 9 0.59 – 135
Pearson χ2 test p< 0.001
Injected illicit drugs other than IPED
Yes 19 2 11% 11 1.87 – 63.95 †
No/not reported 376 4 1.1% 1
Fisher’s exact test p= 0.029
Ever had an abscess/sore/open wound at the injection site?
Yes 27 2 7.4% 7.3 1.27 – 41.69 77 3.27 – 1795
No/not sure 368 4 1.1% 1.0 1.0
Fisher’s exact test p= 0.057
Taken or used any prescribed medication in the last year?
Yes 111 5 4.5% 13 1.54 – 116 †
No/not sure 284 1 0.4% 1
Fisher’s exact test p= 0.008
Have you got advice from a SH/STI clinic in the last year?
Yes 68 4 5.9% 10 1.82 – 56.6 24 1.03 – 542
No/not sure 327 2 0.6% 1 1.0
Fisher’s exact test p= 0.009
Have you ever been vaccinated against hepatitis B?
Yes 90 4 4.4% 7.0 1.27 – 39.1 †
No/not sure 305 2 0.7% 1.0
Fisher’s exact test p= 0.026
Have you ever had a blood test for hepatitis C?
Yes 81 4 4.7% 7.6 1.37 – 42.3 †
No/not sure 308 2 0.9% 1.0
Fisher’s exact test p= 0.021
Have you ever had a blood test for HIV?
Yes 122 4 3.3% 4.6 0.83 – 25.4 †
No/not sure 273 2 0.7% 1.0
Fisher’s exact test p= 0.076
Ever shared a needle, syringe or vial?
Yes 35 2 5.7% 5.4 0.95 – 30.6 †
No/not sure 360 4 1.1% 1.0
Fisher’s exact test p= 0.091
Anti-HBc 395 26 6.6%
Have you got advice from a SH/STI clinic in the last year?
Yes 68 10 14.7% 1.0 1.0
No/not sure 327 16 4.9% 3.4 1.4 – 7.7 3.8 1.6 – 8.9
Fisher’s exact test p= 0.006
Subcutaneous injection in the last year?
Yes 154 6 3.9% 1.0 1.0
No/not sure 241 20 8.3% 2.2 0.88 – 5.7 2.6 0.99 – 6.7
Pearson χ2 test p= 0.085
Continued
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approach for IPED injectors is unknown and cannot cur-
rently be assessed due to the very limited knowledge on
the size and nature of this group.3 5 The use of NSPs to
access this group was a pragmatic approach; community-
based recruitment approaches, such as Respondent
Driven Sampling and Time-Location Sampling, that are
often advocated for hard to reach populations43 are pos-
sible alternatives. However, these are likely to be difﬁcult
to implement with this group due to the diversity of the
drugs used, the clandestine and close-knit nature of this
group and because drug use usually takes place in
private settings (such as homes or gyms).3 5 The ﬁndings
here also rely on self-reported behaviours—though their
reliability has not been assessed among IPED users,
these have been found to be reliable for psychoactive
drug injectors44 45—and infection with BBVs has been
determined by laboratory-based biological data from the
testing of oral-ﬂuid samples. While oral-ﬂuid testing is
highly sensitive for anti-HIV, the sensitivity is reduced for
anti-HCV and anti-HBc.39 While this is the largest study
of BBVs in this population, the sample size still restricts
its power, and consequently caution is needed when
attempting to generalise these ﬁndings to the wider
population of IPED injectors.
The levels of HIV and anti-HBc are higher than in the
only previous UK study to measure these in IPED
Table 3 Continued
Total Positive
Unadjusted odds
ratio with 95% CI
Adjusted odds ratio
with 95% CI
Anti-HCV 395 20 5.1%
Age, years
Under 25 106 4 3.8% 1.0 †
25–34 134 3 2.2% 0.58 0.13 – 2.7
35 and over 107 10 9.3% 2.6 0.80 – 8.7
Not Reported 48 3 6.3% 1.7 0.37 – 7.9
Pearson χ2 test p= 0.078
Injected illicit drugs other than IPED
Yes 19 3 15.8% 4.0 1.1 – 15 4.4 1.1 – 17.2
No/not Sure 376 17 4.5% 1.0 1.0
Fisher’s exact test p= 0.064
Taken or used any prescribed medication in the last year?
Yes 111 10 9.0% 2.7 1.1 – 7 †
No/not sure 284 10 3.5% 1.0
Pearson χ2 test p= 0.025
Have you ever had a blood test for hepatitis C?
Yes 85 8 9.4% 1.7 0.55 – 5.6 †
No 221 7 3.2% 0.5 0.17 – 1.8
Not sure 89 5 5.6% 1.0
Pearson χ2 test p= 0.080
Taken PDE5i: Viagra/cialis
Yes 26 5 19% 5.6 1.9 – 17 6.0 1.9 – 18
No 369 15 4.1% 1.0 1.0
Fisher’s exact test p= 0.007
Injected insulin (as IPED)
Yes 22 4 18% 5.0 1.5 – 16 †
No 373 16 4.3% 1.0
Fisher’s exact test p= 0.019
Other injected IPED (inc. EPO, IGF-1 and Nubain)
Yes 20 3 15% 3.7 0.99 – 14 †
No 375 17 4.5% 1.0
Fisher’s exact test p= 0.073
Ever shared a needle, syringe or vial?
Yes 35 4 11% 2.8 0.87 – 8.8 †
No/not sure 360 16 4% 1.0
Fisher’s exact test p= 0.090
*Combined variable entered into the final model due to an interaction between age and reporting male sexual partners: with 77% of those with
male sexual partners aged over 35 years compared with 25% of those not reporting male sexual partners.
†Not in the final model.
SH/STI, sexual health or sexual transmitted infections clinic; Anti-HCV, antibodies to the hepatitis C virus; Anti-HBc, antibodies to the hepatitis
B core antigen; EPO, erythropoietin; IGF-1, insulin–like growth factor 1; IPED, image and performance enhancing drugs; PDE5i,
phosphodiesterase type 5 inhibitor.
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injectors. Undertaken >10 years ago using a similar meth-
odology, this found no HIV and an anti-HBc prevalence
of 2%;20 suggesting that the prevalence of these infec-
tions among IPED injectors might have increased over
time. Exposure to BBVs among IPED injectors appears to
be associated with sexual risks and the injection of psy-
choactive drugs; although injecting psychoactive drugs is
rare among IPED injectors, unprotected sex with mul-
tiple partners is common. The sharing of injecting equip-
ment or drug vials among IPED injectors at 8.9% is much
less common than among injectors of psychoactive drugs
(in 2011, 37% of psychoactive drug injectors reported
recently sharing injecting equipment40). Though expos-
ure was not associated with sharing in the multivariate
analyses in this study, BBV transmission through IPED
injection cannot be excluded as this study may have
lacked sufﬁcient power to detect this.
The associations between having HIV and the use of
SH/STI clinics and having male sexual partners suggest
that HIV transmission among IPED injectors might be
related to sexual activity. This association may reﬂect AS
use by some HIV positive gay and bisexual men to mask
the longer-term effects of HIV infection.35 The associ-
ation with having an abscess/wound at the injection site
probably reﬂects the greater vulnerability of PWID with
HIV to injection-related bacterial infections.46 47 The
association between exposure to HBV and having
obtained advice from an SH/STI clinic is again sugges-
tive of a role for sexual risk in infection, particularly as
sexual transmission is the main route by which HBV is
now acquired within the UK.48 The association between
having anti-HBc and not injecting subcutaneously sug-
gests that certain patterns of IPED use might be related
to increased risk, as some IPEDs are only injected sub-
cutaneously and others only intramuscularly, and many
users take several types.3 8 12–14 Exposure to HCV,
however, would appear to be associated with the injec-
tion of psychoactive drugs, an association that has been
previously noted6; this ﬁnding might reﬂect more fre-
quent injecting in this subgroup. Sexual activity may also
play a role, assuming that the use of PDE5i is related to
improving or maintaining sexual performance. These
associations all require further investigation.
The level sharing found here was in line with that in pre-
vious studies of injecting risk among IPED
users.20 28–30 32 33 35 The association between sharing and
subcutaneous injection suggests that sharing—like HBV
exposure—may be associated with certain patterns of IPED
use. As in previous studies of IPED injectors, sexual activity
was common and condom use was poor.20 28 34 Condom
use was higher among those with male sexual partners and
lower among those who reported snorting cocaine. The
more frequent use of condoms by gay and bisexual men
probably reﬂects an awareness of their increased HIV risk.42
The association with cocaine use might possibly be related
to its use as a sexual stimulant, with this possibly related to
attempts to counteract the reduced libido experienced on
discontinuation of AS use or in the periods between
courses of AS use (‘off-cycles’).14 In part, this effect may be
as a result of the decrease in endogenous testosterone pro-
duction,49 which is why IPED users self-treat with human
chorionic gonadotrophin in an attempt to stimulate
endogenous production, with PDE5i used to symptomatic-
ally treat erectile dysfunction.5 14 50 Increased libido follow-
ing AS administration is also reported by users,14 33 34 51
with similar effects being reported following the use of
drugs such as melanotan-II.12
Associations were found between psychoactive drug
use and sharing and poor condom use. IPED users who
also use psychoactive drugs may be a higher risk—or
perhaps less risk averse—subgroup. While this needs
further investigation, it suggests—considering the sub-
stantial levels of psychoactive drug use found here and
in previous studies6 8 28 35 36—that those using IPED
and psychoactive drugs should be an important target
group for harm reduction interventions.
This study indicates that those providing services to
PWID—particularly NSPs, outreach services and general
practitioners—should be alert to the needs of those who
use IPEDs. In particular, they need to be aware of the
range of drugs that may be used by this group and of the
associated injecting practices, as these differ from those of
psychoactive drug injectors. Considering the BBV preva-
lence and levels of risk found, specialist services for PWID
need to engage with IPED users and ensure that they have
access to appropriate injecting equipment and targeted
harm reduction advice. They should also ensure that this
group has access to testing for BBVs, hepatitis B vaccina-
tions, sexual health services and condoms.
Our ﬁndings suggest that sexual risk and the use, and
particularly the injection, of psychoactive drugs are pos-
sibly the most important factors associated with BBV trans-
mission among IPED injectors. The transmission of HIV
and other BBVs through the injecting of IPED cannot be
excluded, and this is certainly possible as equipment
sharing does occur. However, the participants in this study
were largely recruited through NSPs providing injecting
equipment and advice. IPED injectors not in contact with
NSPs may have a different risk proﬁle and infection risk.
Even so, our ﬁndings suggest the need for targeted inter-
ventions to address sexual health needs, psychoactive drug
use and the injection practices among IPED injectors.
Considering the limitations of this study, a larger study
recruiting from a wider range of settings and collecting
dried-blood samples is needed to more fully examine
prevalence and, in particular, the associated risk factors
and thus the role of IPED injection in transmission of HIV
and other BBVs.
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